PL2248517T3 - Stężone formulacje farmaceutyczne stabilizujące komórki tuczne - Google Patents
Stężone formulacje farmaceutyczne stabilizujące komórki tuczneInfo
- Publication number
- PL2248517T3 PL2248517T3 PL09006294T PL09006294T PL2248517T3 PL 2248517 T3 PL2248517 T3 PL 2248517T3 PL 09006294 T PL09006294 T PL 09006294T PL 09006294 T PL09006294 T PL 09006294T PL 2248517 T3 PL2248517 T3 PL 2248517T3
- Authority
- PL
- Poland
- Prior art keywords
- concentrated
- pharmaceutical formulations
- mast cell
- cell stabilizing
- stabilizing pharmaceutical
- Prior art date
Links
- 210000003630 histaminocyte Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006294.4A EP2248517B1 (en) | 2009-05-08 | 2009-05-08 | Concentrated mast cell stabilizing pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2248517T3 true PL2248517T3 (pl) | 2014-08-29 |
Family
ID=40934943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09006294T PL2248517T3 (pl) | 2009-05-08 | 2009-05-08 | Stężone formulacje farmaceutyczne stabilizujące komórki tuczne |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9198859B2 (pl) |
| EP (1) | EP2248517B1 (pl) |
| JP (1) | JP5863641B2 (pl) |
| ES (1) | ES2457442T3 (pl) |
| PL (1) | PL2248517T3 (pl) |
| WO (1) | WO2010128111A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1962805T3 (pl) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| PT2852391T (pt) | 2012-05-21 | 2022-02-18 | Insmed Inc | Sistemas para tratamento de infeções pulmonares |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CN105377037A (zh) | 2013-05-23 | 2016-03-02 | Az治疗公司 | 用于递送色甘酸的方法 |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| DK3104853T3 (da) | 2014-02-10 | 2019-12-09 | Respivant Sciences Gmbh | Behandling med mastcellestabilisatorer til systemiske forstyrrelser |
| US20160367520A1 (en) * | 2014-02-10 | 2016-12-22 | Patara Pharma, LLC | Mast cell stabilizers for lung disease treatment |
| MX376012B (es) | 2014-05-15 | 2025-03-07 | Insmed Inc | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
| WO2017027402A1 (en) * | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| CN109922800B (zh) | 2016-08-31 | 2023-06-13 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
| AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| EP3522983A4 (en) * | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
| KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| MX2020000577A (es) | 2017-07-20 | 2020-09-10 | Aztherapies Inc | Formulaciones en polvo de cromolina sodica e ibuprofeno. |
| JP7460534B2 (ja) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| US20210113467A1 (en) | 2018-05-02 | 2021-04-22 | Robert Worsham | Methods for the manufacture of liposomal drug formulations |
| JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
| SG11202106117SA (en) | 2018-12-10 | 2021-07-29 | Massachusetts Gen Hospital | Cromolyn esters and uses thereof |
| CN110960514A (zh) * | 2019-12-23 | 2020-04-07 | 杭州百诚医药科技股份有限公司 | 一种吸入用复方多索茶碱溶液及其制备方法 |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2167300B (en) * | 1984-11-23 | 1988-11-23 | Fisons Plc | Formulations |
| GB8520133D0 (en) | 1985-08-10 | 1985-09-18 | Fisons Plc | Mixtures |
| DE3700379A1 (de) | 1987-01-08 | 1988-07-21 | Mann Gerhard Chem Pharm Fab | Konservierte augentropfen mit einem gehalt an cromoglicinsaeure |
| EP0413583A3 (en) | 1989-08-18 | 1991-07-17 | Dey Laboratories; Inc. | Clear, stable cromolyn formulation |
| GB9214390D0 (en) * | 1992-07-07 | 1992-08-19 | Fisons Plc | Formulations |
| DE19539532C2 (de) | 1995-10-24 | 1999-02-25 | Mann Gerhard Chem Pharm Fab | Ophthalmisches Cromoglicat-Gelpräparat |
| WO1997024142A1 (fr) | 1995-12-27 | 1997-07-10 | Showa Yakuhin Kako Co., Ltd. | Composition aqueuse contenant de l'acide cromoglycique |
| US20040045546A1 (en) * | 2002-09-05 | 2004-03-11 | Peirce Management, Llc | Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use |
| DE102005038619A1 (de) | 2005-08-16 | 2007-02-22 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments |
| US8263645B2 (en) | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| SI1991201T1 (en) * | 2006-02-10 | 2018-08-31 | Pari Pharma Gmbh | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY |
| EP2030644A1 (en) * | 2007-08-31 | 2009-03-04 | PARI Pharma GmbH | Aerosols for sinunasal drug delivery |
| DE102007056462B4 (de) | 2007-11-23 | 2011-10-27 | Pari Pharma Gmbh | Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen |
-
2009
- 2009-05-08 PL PL09006294T patent/PL2248517T3/pl unknown
- 2009-05-08 ES ES09006294.4T patent/ES2457442T3/es active Active
- 2009-05-08 EP EP09006294.4A patent/EP2248517B1/en not_active Not-in-force
-
2010
- 2010-05-06 JP JP2012509043A patent/JP5863641B2/ja not_active Expired - Fee Related
- 2010-05-06 WO PCT/EP2010/056197 patent/WO2010128111A1/en not_active Ceased
-
2011
- 2011-11-08 US US13/291,488 patent/US9198859B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2248517A1 (en) | 2010-11-10 |
| US9198859B2 (en) | 2015-12-01 |
| EP2248517B1 (en) | 2014-03-26 |
| WO2010128111A1 (en) | 2010-11-11 |
| JP2012526084A (ja) | 2012-10-25 |
| JP5863641B2 (ja) | 2016-02-16 |
| ES2457442T3 (es) | 2014-04-25 |
| US20120118991A1 (en) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2248517T3 (pl) | Stężone formulacje farmaceutyczne stabilizujące komórki tuczne | |
| HUS2000009I1 (hu) | Kétrétegû tabletta készítmények | |
| PL3061445T3 (pl) | Silnie stężone preparaty farmaceutyczne | |
| IL225415A0 (en) | Electrolytic formulations | |
| ZA201106050B (en) | Dye-polymers formulations | |
| BRPI1016228A2 (pt) | formulações de eletrólito compatibilizadas | |
| ZA201200719B (en) | Pharmaceutical formulation | |
| EP2512490A4 (en) | S-ADENOSYLMETHIONINE FORMULATIONS WITH INCREASED BIOAVAILABILITY | |
| IL219264A0 (en) | Docetaxel formulations with lipoic acid | |
| IL269369A (en) | The vehicles are improved | |
| GB0919210D0 (en) | Formulations | |
| GB0909134D0 (en) | Cathode | |
| IL217887A0 (en) | Concentrated polypeptide formulations with reduced viscosity | |
| AP2013006687A0 (en) | Formulations | |
| PT2568970T (pt) | Formulações farmacêuticas estáveis contendo um anti-histamínico | |
| EP2473168A4 (en) | PHARMACEUTICAL FORMULATIONS FOR INDIBULIN | |
| IL217390A0 (en) | Formulations | |
| SI2261444T1 (sl) | Drog | |
| AP2013006689A0 (en) | Formulations | |
| HU0900086V0 (en) | Mast | |
| GB0917744D0 (en) | Formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations | |
| GB201012046D0 (en) | Pharmaceutical formulations | |
| GB0914489D0 (en) | Improved formulations | |
| AU2009905633A0 (en) | Formulations |